fa77d98c-c26c-4a45-8c0d-3cb11173eb38
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 31.1594798083504
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.380
- MYC_TARGETS_V2+0.330
- MYC_TARGETS_V1+0.290
- DNA_REPAIR+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- E2F_TARGETS+0.190
- ADIPOGENESIS+0.160
- MYOGENESIS+0.140
- FATTY_ACID_METABOLISM+0.130
- UV_RESPONSE_UP+0.110
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.390
- IL6_JAK_STAT3_SIGNALING-0.350
- HEDGEHOG_SIGNALING-0.340
- PROTEIN_SECRETION-0.340
- INTERFERON_GAMMA_RESPONSE-0.300
- UV_RESPONSE_DN-0.300
- WNT_BETA_CATENIN_SIGNALING-0.270
- INFLAMMATORY_RESPONSE-0.260
- ANDROGEN_RESPONSE-0.220
- KRAS_SIGNALING_UP-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR17866857 | — | — | 0.842 |
| 2 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.842 |
| 3 | AUR-AG0J-TTM1-A-1-0-R-A743-41 | — | E | 0.815 |
| 4 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.814 |
| 5 | TCGA-KU-A6H7-06A-21R-A31N-07 | — | — | 0.808 |
| 6 | 63bab58e-1dfd-43df-8188-4b8d766913f3 | — | — | 0.807 |
| 7 | TCGA-P3-A6T6-01A-11R-A34R-07 | — | — | 0.806 |
| 8 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.806 |
| 9 | MNG563 | — | — | 0.804 |
| 10 | TCGA-E2-A574-01A-11R-A29R-07 | — | E | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |